Biosimilars are generally cheaper than originator biologics and may also incite price reductions of originator biologics; however, the benefit of biosimilars is not limited to cost savings.

Competition in European off-patent biologics and biosimilar markets may expand access to the treatment, improve cost effectiveness of the treatment, increase the number of healthcare professionals, and stimulate an incremental therapeutic innovation.